Frontotemporal Lobar Degeneration (FTLD)FRONTAL-PEGNCT07110207
Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
A study testing Blood test, Interrogation of the subject and Cognitive assessment in people with Frontotemporal Lobar Degeneration (FTLD), run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Frontotemporal Lobar Degeneration (FTLD)
- What is being tested?
- Blood test, Interrogation of the subject and Cognitive assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 18 Aug 2025to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Person who has given their free and informed consent
- Person of legal age
- Fasting > 2 hours before PEG measurement
- Body Mass Index (BMI) < 30 kg/m² (according to medical record data)
- DLFT: diagnostic criteria for established or probable DLFT
Who cannot join
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship, trusteeship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding women
- MMSE score < 15 and/or MoCA score < 10
- Known COVID-19 infection within 6 months prior to inclusion
Show all 10Show fewer
- Active smokers (> 4 cigarettes per day on a regular basis)
- Subject with a pacemaker (contraindication for bioelectrical impedance analysis)
- Subject with diabetes (type 1 or type 2)
- Taking medication (during the study) that interferes with taste
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Dijon Bourgogne
Dijon
Agnès JACQUIN-PIQUES, 03 80 29 59 02, agnes.jacquin-piques@chu-dijon.fr
About this study
The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease.
Patients with FTLD often experience olfactory disorders (= sense of smell) and eating disorders: increased appetite, increased food intake and excessive consumption of sugary foods and snacking. This often leads to excessive weight gain. These eating disorders are still poorly understood at present.
Read more
In this context, we hypothesise that an alteration in the gustatory pathway - i.e. the way in which the brain perceives taste - could contribute to the eating disorders frequently observed in frontotemporal dementia (FTD), particularly in the marked attraction to sweet foods. We therefore wish to objectively evaluate the taste response to a sweet solution (sucrose) in patients with FTLD, using taste evoked potentials (TEPs). Taste evoked potentials are a reliable and reproducible technique for assessing brain activity in response to taste stimulation. One of their advantages is that they are non-invasive.
This study will document, for the first time in this disease, the characteristics of cortical (brain) processing of taste information.
The FRONTAL-PEG study is an interventional, regional, single-centre study conducted at the Dijon University Hospital, in collaboration with the CMRR (Memory, Resources and Research Centre) and the CSGA (Centre for Taste and Food Sciences).
All investigations are carried out at the CSGA (building adjacent to the Dijon University Hospital), with the exception of blood tests, which are carried out at the Dijon University Hospital.
The total duration of participation in the study is one morning. No follow-up is planned at the end of the study.
- Conditions
- Frontotemporal Lobar Degeneration (FTLD)
- Being tested
- Blood test, Interrogation of the subject, Cognitive assessment, Nutritional assessment, Taste tests
- Medical subject headings
- Frontotemporal Lobar Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood testBiological
Metabolic measurements and measurements of hormones related to food intake
Interrogation of the subjectOther
Collection of socio-demographic data, medical and family history, medication
Cognitive assessmentOther
MMSE and MoCA cognitive tests
Nutritional assessmentOther
Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)
Taste testsOther
Recording of PEGs in response to a sucrose solution (prepared beforehand)
Sucrose taste detection testOther
Triangular test
| Study group | Role | What they receive |
|---|---|---|
| Patients with frontotemporal lobar degeneration | Experimental | Not described Receives: Biological: Blood test; Other: Interrogation of the subject; Other: Cognitive assessment; Other: Nutritional assessment; Other: Taste tests; Other: Sucrose taste detection test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average latency of taste evoked potentials
Measured: After a fasting period of at least two hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2025
- Study start18 Aug 2025
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Frontotemporal Lobar Degeneration (FTLD)Studies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07110207
- Sponsor's protocol ID
- JACQUIN 2025
- Acronym
- FRONTAL-PEG
- Status last verified
- Aug 2025
- First submitted
- 31 Jul 2025
- Last updated
- 24 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
- ClinicalTrials.gov ID
- NCT07110207
- Acronym / sponsor ID
- FRONTAL-PEG / JACQUIN 2025
- Conditions
- Frontotemporal Lobar Degeneration (FTLD)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 18 Aug 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 7 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease.
Patients with FTLD often experience olfactory disorders (= sense of smell) and eating disorders: increased appetite, increased food intake and excessive consumption of sugary foods and snacking. This often leads to excessive weight gain. These eating disorders are still poorly understood at present.
In this context, we hypothesise that an alteration in the gustatory pathway - i.e. the way in which the brain perceives taste - could contribute to the eating disorders frequently observed in frontotemporal dementia (FTD), particularly in the marked attraction to sweet foods. We therefore wish to objectively evaluate the taste response to a sweet solution (sucrose) in patients with FTLD, using taste evoked potentials (TEPs). Taste evoked potentials are a reliable and reproducible technique for assessing brain activity in response to taste stimulation. One of their advantages is that they are non-invasive.
This study will document, for the first time in this disease, the characteristics of cortical (brain) processing of taste information.
The FRONTAL-PEG study is an interventional, regional, single-centre study conducted at the Dijon University Hospital, in collaboration with the CMRR (Memory, Resources and Research Centre) and the CSGA (Centre for Taste and Food Sciences).
All investigations are carried out at the CSGA (building adjacent to the Dijon University Hospital), with the exception of blood tests, which are carried out at the Dijon University Hospital.
The total duration of participation in the study is one morning. No follow-up is planned at the end of the study.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with frontotemporal lobar degeneration | Experimental | Biological: Blood test, Other: Interrogation of the subject, Other: Cognitive assessment, Other: Nutritional assessment, Other: Taste tests, Other: Sucrose taste detection test |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Person who has given their free and informed consent
- Person of legal age
- Fasting > 2 hours before PEG measurement
- Body Mass Index (BMI) < 30 kg/m² (according to medical record data)
- DLFT: diagnostic criteria for established or probable DLFT
Key exclusion criteria (10 listed)
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship, trusteeship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding women
- MMSE score < 15 and/or MoCA score < 10
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood testMetabolic measurements and measurements of hormones related to food intake | Biological | Patients with frontotemporal lobar degeneration |
| Interrogation of the subjectCollection of socio-demographic data, medical and family history, medication | Other | Patients with frontotemporal lobar degeneration |
| Cognitive assessmentMMSE and MoCA cognitive tests | Other | Patients with frontotemporal lobar degeneration |
| Nutritional assessmentAnthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg) | Other | Patients with frontotemporal lobar degeneration |
| Taste testsRecording of PEGs in response to a sucrose solution (prepared beforehand) | Other | Patients with frontotemporal lobar degeneration |
| Sucrose taste detection testTriangular test | Other | Patients with frontotemporal lobar degeneration |
Primary outcome
Average latency of taste evoked potentials
Time frame: After a fasting period of at least two hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2025.
Related trials for Frontotemporal Lobar Degeneration (FTLD)
Enrolling by invitationPhase 2
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
PSP - Progressive Supranuclear Palsy
Enrolling by invitationPhase 2
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
PSP - Progressive Supranuclear Palsy
RecruitingObservational study
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Not yet recruitingObservational study
Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease
Alzheimer's Disease, Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood test, Interrogation of the subject and Cognitive assessment in people with Frontotemporal Lobar Degeneration (FTLD), run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Agnès JACQUIN-PIQUES (03 80 29 59 02, agnes.jacquin-piques@chu-dijon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average latency of taste evoked potentials (time frame: After a fasting period of at least two hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2025.